Participants will complete surveys within 1 week of the surgical consult and 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients/surgeons will also have their surgical consultation audio-recorded. conditions: Breast Cancer Stage 0 conditions: Breast Cancer Stage I conditions: Breast Cancer Stage II conditions: Breast Cancer Stage III studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The study is a pragmatic, Type II hybrid effectiveness-implementation, stepped-wedge design that will incorporate a mixed-methods approach to test the efficacy and evaluate the implementation of the CONSYDER intervention primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 800 type: ESTIMATED name: CONSYDER decision aid measure: Pre-surgical decisional conflict as measured by the Decisional Conflict Scale (DCS) measure: Use of CONSYDER pre-consult measure: Knowledge as measured by adapted Breast Cancer Surgery Decision Quality Instrument (BCS -DQI) measure: Treatment goals and preferences as measured by adapted Breast Cancer Surgery Decision Quality Instrument (BCS-DQI) measure: Anxiety, as measured with the 8-item Patient Reported Outcomes Measurement Information System (PROMIS) - Anxiety - Short Form measure: Self-efficacy in communication as measured by the Perceived Efficacy in Patient-Physician Interactions scale (PEPPI). measure: Decisional regret as measured by the Decision Regret Scale (DRS) measure: Receipt of contralateral prophylactic mastectomy measure: Fidelity of implementation of CONSYDER via patient portal email measure: Use of CONSYDER post-consult measure: Frequency of CONSYDER use pre-consult measure: Frequency of CONSYDER use post-consult sex: FEMALE minimumAge: 18 Years maximumAge: 44 Years stdAges: ADULT facility: Yale Cancer Center status: RECRUITING city: New Haven state: Connecticut zip: 06510 country: United States name: Rachel Greenup, MD, MPH role: CONTACT phone: 203-737-2966 email: rachel.greenup@yale.edu name: Rachel Greenup, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 41.30815 lon: -72.92816 facility: Dana-Farber Cancer Institute status: RECRUITING city: Boston state: Massachusetts zip: 02215 country: United States name: Ann Partridge, MD, MPH role: CONTACT phone: 617-632-3800 email: ann_partridge@dfci.harvard.edu name: Ann Partridge, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Weill Cornell Medicine status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Shoshana Rosenberg, ScD, MPH role: CONTACT phone: 646-962-8041 email: shr4009@med.cornell.edu name: Darima Dorzhieva role: CONTACT phone: 646-962-8666 email: dad4011@med.cornell.edu name: Shoshana Rosenberg, ScD, MPH role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 facility: Duke Cancer Institute status: RECRUITING city: Durham state: North Carolina zip: 27710 country: United States name: Jennifer Plichta, MD, MS role: CONTACT phone: 919-681-9156 email: jennifer.plichta@duke.edu name: Jennifer Plichta, MD, MS role: PRINCIPAL_INVESTIGATOR lat: 35.99403 lon: -78.89862 hasResults: False